| Recruiting | A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) NCT07213804 | Eli Lilly and Company | Phase 3 |
| Recruiting | OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy NCT06466382 | Swiss GO Trial Group | N/A |
| Recruiting | MIRRORS-FROZEN - Comparing Open Vs Robotic Surgery in the Management of Women with Complex Pelvic Adnexal Mass NCT06638593 | Royal Surrey County Hospital NHS Foundation Trust | N/A |
| Recruiting | Agnostic Therapy in Rare Solid Tumors NCT06638931 | Instituto do Cancer do Estado de São Paulo | Phase 2 |
| Unknown | SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery NCT06223763 | Clinica Universidad de Navarra, Universidad de Navarra | — |
| Unknown | MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer NCT05960630 | Royal Surrey County Hospital NHS Foundation Trust | N/A |
| Active Not Recruiting | Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovar NCT05605535 | CanariaBio Inc. | Phase 2 |
| Active Not Recruiting | AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Can NCT05617755 | Arsenal Biosciences, Inc. | Phase 1 |
| Recruiting | BP1001-A in Patients With Advanced or Recurrent Solid Tumors NCT04196257 | Bio-Path Holdings, Inc. | Phase 1 |
| Active Not Recruiting | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian NCT05257408 | Corcept Therapeutics | Phase 3 |
| Terminated | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors NCT05194072 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Active Not Recruiting | Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Can NCT05116189 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cance NCT04807166 | Wenjun Cheng | Phase 2 |
| Unknown | Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian NCT04556071 | Xiaoxiang Chen | Phase 2 |
| Recruiting | MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) NCT04111978 | Swiss GO Trial Group | Phase 3 |
| Active Not Recruiting | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal De NCT04498117 | CanariaBio Inc. | Phase 3 |
| Recruiting | Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer NCT04794322 | Massachusetts General Hospital | — |
| Completed | An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cance NCT01932125 | Hoffmann-La Roche | Phase 4 |
| Completed | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (o NCT03648489 | Imperial College London | Phase 2 |
| Completed | Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of M NCT03593681 | Boston Scientific Corporation | — |
| Recruiting | Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers NCT03976999 | Institut du Cancer de Montpellier - Val d'Aurelle | N/A |
| Completed | Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer NCT02903771 | Kazia Therapeutics Limited | Phase 1 |
| Unknown | HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life NCT03000192 | University Hospital Southampton NHS Foundation Trust | — |
| Completed | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors NCT02658214 | AstraZeneca | Phase 1 |
| Completed | Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy NCT02786524 | University of Michigan | N/A |
| Unknown | DNA Single Nucleotide Polymorphisms as Predictors of Toxicity NCT02478476 | OvaGene Oncology, Inc. | — |
| Completed | Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients NCT02444195 | University of Michigan | N/A |
| Completed | A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatme NCT01846611 | Janssen Research & Development, LLC | Phase 3 |
| Withdrawn | 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant NCT01766622 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Terminated | Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer NCT01681368 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Re NCT01478685 | Celgene | Phase 1 |
| Completed | Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients Wit NCT01462890 | AGO Study Group | Phase 3 |
| Terminated | Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer NCT01279291 | Kyowa Kirin Co., Ltd. | Phase 1 |
| Withdrawn | Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary NCT01131039 | Emory University | Phase 2 |
| Withdrawn | A Prospective Trial of COXEN Chemotherapy Prediction NCT01228942 | University of Virginia | N/A |
| Completed | Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Ca NCT01313078 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallo NCT00698451 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 |
| Terminated | Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT00445549 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pharmacogenomics of Paclitaxel in Ovarian Cancer NCT00415207 | University of Southern Denmark | — |
| Completed | Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") NCT00391118 | Eli Lilly and Company | Phase 2 |
| Terminated | ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fal NCT00407407 | Celgene | Phase 1 |
| Completed | Pharmacogenomics of Paclitaxel in Ovarian Cancer NCT00415181 | University of Southern Denmark | — |
| Completed | Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas NCT00443196 | Pierian Biosciences | Phase 2 / Phase 3 |
| Completed | Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunct NCT00189345 | AGO Study Group | Phase 2 |
| Completed | Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tub NCT00074867 | Pfizer | Phase 2 |
| Completed | Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peri NCT00063401 | Eli Lilly and Company | Phase 2 |
| Completed | Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response NCT00103545 | AGO Study Group | Phase 1 / Phase 2 |
| Completed | OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers NCT00112086 | Japan Clinical Oncology Group | Phase 2 |
| Completed | An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemot NCT00191646 | Eli Lilly and Company | Phase 3 |
| Completed | A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. NCT00191607 | Eli Lilly and Company | Phase 3 |
| Completed | EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer NCT00035100 | Novartis Pharmaceuticals | Phase 2 |